Pirfenidone for diabetic nephropathy.

  title={Pirfenidone for diabetic nephropathy.},
  author={Kumar Sharma and Joachim H. Ix and Anna Vachaparampil Mathew and Monique E Cho and Axel C Pflueger and Stephen R. Dunn and Barbara Francos and Shoba Sharma and Bonita E Falkner and Tracy A McGowan and Michael J. Donohue and Satish P Ramachandrarao and Ronghui Xu and Fernando C Fervenza and Jeffrey B. Kopp},
  journal={Journal of the American Society of Nephrology : JASN},
  volume={22 6},
Pirfenidone is an oral antifibrotic agent that benefits diabetic nephropathy in animal models, but whether it is effective for human diabetic nephropathy is unknown. We conducted a randomized, double-blind, placebo-controlled study in 77 subjects with diabetic nephropathy who had elevated albuminuria and reduced estimated GFR (eGFR) (20 to 75 ml/min per 1.73 m²). The prespecified primary outcome was a change in eGFR after 1 year of therapy. We randomly assigned 26 subjects to placebo, 26 to… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 83 extracted citations


Publications referenced by this paper.
Showing 1-10 of 38 references

Similar Papers

Loading similar papers…